The estimated Net Worth of Michael J. Yang is at least $3.06 Millón dollars as of 14 August 2024. Mr. Yang owns over 2,000 units of Acadia Pharmaceuticals Inc stock worth over $115,319 and over the last 8 years he sold ACAD stock worth over $0. In addition, he makes $2,943,820 as Executive Vice President y Chief Commercial Officer at Acadia Pharmaceuticals Inc.
Michael has made over 8 trades of the Acadia Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of ACAD stock worth $25,800 on 14 August 2024.
The largest trade he's ever made was exercising 105,479 units of Acadia Pharmaceuticals Inc stock on 12 December 2019 worth over $3,279,342. On average, Michael trades about 7,326 units every 80 days since 2017. As of 14 August 2024 he still owns at least 7,230 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Yang stock trades at the bottom of the page.
Michael J. Yang serves as Executive Vice President, Chief Commercial Officer of the Company. Mr. Yang is our Executive Vice President, Chief Commercial Officer and has been with our company since March 2017. Mr. Yang joined us from Janssen Pharmaceutical Companies of Johnson & Johnson, where he served as President of Janssen Biotech Inc. and was responsible for building Janssen’s U.S. Immunology business, generating more than $8 billion in annual revenues. Mr. Yang began his career at Johnson & Johnson in 1997 and held numerous senior commercial positions such as President, CNS where he was responsible for growing the anti-psychotic long-acting therapy portfolio. His broad background of commercialization and general management experience also includes roles as the Worldwide General Manager of the Medical Device companies of Therakos, Inc and Veridex, LLC, where he launched new platforms, expanded global revenues and diversified the product lines. Prior to that, Mr. Yang was Vice President of Sales and Marketing, Oncology at Ortho Biotech Inc. He currently serves on the board of directors of Akcea Therapeutics, Inc. Mr. Yang earned his B.S. in business administration, marketing from San Diego State University.
As the Executive Vice President y Chief Commercial Officer of Acadia Pharmaceuticals Inc, the total compensation of Michael Yang at Acadia Pharmaceuticals Inc is $2,943,820. There are 2 executives at Acadia Pharmaceuticals Inc getting paid more, with Stephen Davis having the highest compensation of $7,631,250.
Michael Yang is 58, he's been the Executive Vice President y Chief Commercial Officer of Acadia Pharmaceuticals Inc since 2017. There are 7 older and 8 younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... y Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: